Enzon Pharmaceuticals Inc

Chart & Performance

D1W1MN

P/E

7.82

P/S

234.06

EPS

0.01

Div Yield, %

—

Shrs. gr., 5y

10.91%

Rev. gr., 5y

-33.96%

Revenues

26k

Net income

778k

+693.88%

CFO

-14.02%

Dividend

Sep 30, 20190.12 USD/sh

Profile

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

URL

http://enzon.com/

IPO date

Feb 16, 1984

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	26		26 -96.29%
Cost of revenue	1,353	1,044	1,058
Unusual Expense (Income)
NOPBT	(1,327)	(1,044)	(1,032)
NOPBT Margin
Operating Taxes	347	(156)	(200)
Tax Rate
NOPAT	(1,674)	(888)	(832)
Net income	778 693.88%	98 -152.69%	(186) -60.34%
Dividends	(1,275)	(1,275)	(1,275)
Dividend yield	11.01%	18.36%	6.97%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities	42,483	42,483	42,483
Net debt	(46,859)	(47,012)	(46,982)
Cash flow
Cash from operating activities	1,122	1,305	(659)
CAPEX
Cash from investing activities
Cash from financing activities	(1,275)	(1,275)	(1,275)
FCF	(1,674)	(888)	(832)
Balance
Cash	46,859	47,012	46,982
Long term investments
Excess cash	46,858	47,012	46,981
Stockholders' equity	(69,150)	(27,445)	(28,818)
Invested Capital	114,641	73,433	74,708
ROIC
ROCE
EV
Common stock shares outstanding	74,215	74,215	74,215
Price	0.16 66.86%	0.09 -62.07%	0.25 -27.99%
Market cap	11,585 66.86%	6,943 -62.07%	18,305 -27.99%
EV	(35,274)	2,414	13,806
EBITDA	(1,327)	(1,044)	(1,032)
EV/EBITDA	26.58
Interest			646
Interest/NOPBT